Pneumokokkenschutzimpfung

Literatur

• 1 Ständige Impfkommission am Robert Koch-Institut . Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2001.  Epidemiol Bull. 2001;  28/2001 203-218
• 2 Nichol K L, Margolis K L, Wuorenma J, von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.  N Engl J Med. 1994;  331 778-784
• 3 Nichol K L, Lind A L, Margolis K L. et al . The effectiveness of vaccination against influenza in healthy, working adults.  N Engl J Med. 1995;  333 889-893
• 4 Nichol K L, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens.  Arch Intern Med. 1998;  158 1769-1776
• 5 Nichol K L, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.  Ann Intern Med. 1999;  130 397-403
• 6 Shapiro E D, Berg A T, Austrian R. et al . The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.  N Engl J Med. 1991;  325 1453-1460
• 7 Butler J C, Breiman R F, Campbe I JF. et al . Pneumococcal polysaccharide vaccine efficacy.  JAMA. 1993;  270 1826-1831
• 8 French N, Nakiyingi J, Carpenter L M. et al . 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Uganda adults: double-blind, randomized and placebo-controlled trial.  Lancet. 2000;  355 2106-2111
• 9 Moore RA; Wiffen P J, Lipinsky B A. Are the pneumococcal polysaccharide vaccines effective? Metaanalysis of the prospective trials.  BMC Fam Pract. 2000;  1 110
• 10 Christenson B, Lundbergh P, Hedlund J, Örtqvist A. Effects of large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study.  Lancet. 2001;  357 1008-1011
• 11 Meyer F. Pro und Contra Pneumokokkenschutzimpfung.  BDI Rundschreiben. 2001;  8/9 23-26